Last reviewed · How we verify

NCT06623227: TACASD

Effect of Increasing Total Antioxidant Capacity in Autism Spectrum Disorder

ENROLLING BY INVITATION NA Last updated 4 October 2024
What this trial tests

NA trial testing Placebo in Autism Spectrum Disorder in 50 participants. Enrolling by invitation.

Timeline
28 September 2024
Primary endpoint
31 January 2025
30 June 2025

Quick facts

Lead sponsorRinvil Renaldi
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment50
Start date28 September 2024
Primary completion31 January 2025
Estimated completion30 June 2025
Sites1 location across Indonesia

Drugs / interventions tested

Conditions studied

Sponsor

Rinvil Renaldi

Who can join

Adults 3 to 9, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double-blind, randomized, controlled trial (RCT) has the aim to evaluating the effectiveness of increasing Total Antioxidant Capacity (TAC) as add-on intervention in two cohorts of patients with Autism Spectrum Disorder (ASD) who have received Risperidone (0.02-0.06 mg/KgBW) and Behavior Therapy as maintenance therapy. Both groups will receive placebo pill or Vitamin E and C pill using randomization. Clinical Symptoms, Aberrant Behavior and Quality of Life in Children with ASD will be assessed after 12 weeks of treatment in this study. Primary outcome measures of efficacy is Aberrant Behavior Checklist- Irritability (ABC-Irritability) and Secondary outcome measures include Childhood Autism Rating Scale (CARS), Clinical Global Impression Scale - Improvement (CGI-I), The PedsQL and The WHOQOL BREF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vitamin E and C

Trials testing the same drug.

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Rinvil Renaldi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06623227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing